Trials / Completed
CompletedNCT00724529
Post Marketing Surveillance of Remicade
Post Marketing Surveillance of Remicade in Inflammatory Bowel Disease (IBD)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 938 (actual)
- Sponsor
- Janssen Korea, Ltd., Korea · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand the safety and effectiveness of infliximab when used in clinical practice. This is a post-marketing surveillance study.
Detailed description
The investigator will record continuously from the first patient since the day of contract to the numbers of patients of contract based on Remicade approval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Infliximab | Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for. |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2008-07-29
- Last updated
- 2013-01-23
Source: ClinicalTrials.gov record NCT00724529. Inclusion in this directory is not an endorsement.